SMS Pharmaceuticals Limited — PPTs, 10-11-2025: Investor Presentation

**1. Business Performance:**

SMS Pharma reported strong Q2FY26 results with revenue up 23% YoY to ₹242 Cr, EBITDA rising 54% to ₹48 Cr, and PAT jumping 80% to ₹25 Cr. EPS grew 70% to ₹2.84. H1FY26 also saw solid performance: revenue at ₹438 Cr (up 21%), EBITDA at ₹88 Cr (up 35%), and PAT at ₹46 Cr (up 50%). Growth was fueled by volume increases and market share gains across key APIs, particularly in Anti-diabetic, ARV, and Anti-inflammatory segments.

**2. Growth Drivers or Strategy:**

The company is executing a ₹280 Cr capex program for capacity expansion and new API development, targeting completion by November 2026. Backward integration is a strategic focus to protect gross margins and reduce raw material dependency. SMS Pharma plans to double its R&D investment over the next 15 months, aiming for 30 new filings in 30 months to strengthen its product pipeline.

**3. Recent Developments:**

Recent developments include achieving its highest-ever quarterly PAT and successful audits by USFDA and EQDM at its Vizag plant and VKT Pharma, confirming global compliance. The investment in VKT Pharma is now meaningfully contributing to the bottom line.

**4. Key Financial Metrics:**

For Q2FY26, revenue increased 23% YoY to ₹242 Cr, EBITDA rose 54% to ₹48 Cr, PAT surged 80% to ₹25 Cr, and EPS grew 70% to ₹2.84. H1FY26 also saw solid performance: revenue up 21% to ₹438 Cr, EBITDA up 35% to ₹88 Cr, PAT up 50% to ₹46 Cr, and EPS up 42% to ₹5.13.

**5. Management Commentary / Outlook:**

Management anticipates delivering 20% revenue growth and 20% EBITDA margins for FY26. The company aspires to become the global leader in Anti-inflammatory APIs and expects additional revenues from its strategic partnership with Chemo.